Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05836987 · ClinicalTrials.gov registry record · Phase 3

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

A Phase 3 study of Atrial Fibrillation, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 3
Development phase
5,350
Enrollment target
20
Study locations

NCT05836987 is a Phase 3 study of Atrial Fibrillation that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 5,350 participants, above the 2,970-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05836987, a Phase 3 study of Atrial Fibrillation, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 3
Development phase
5,350 participants
Enrollment target
20
Study locations

Study Summary

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

Conditions Studied

Atrial Fibrillation

Interventions

  • DEVICE AFSW Guided DOAC
  • DRUG Continuous DOAC therapy

Study Locations (20)

Florida

  • BayCare Health Systems - Clearwater
  • University of Florida - Gainesville
  • Mayo Clinic - Jacksonville
  • University of Miami - Leonard S. Miller SOM - Miami
  • Sarasota Memorial Health Care System - Sarasota
  • Cleveland Clinic Florida - Stuart
  • Baycare Health Systems Clearwater - Winter Haven

California

  • University of Southern California - Keck School of Medicine - Los Angeles
  • University of California Los Angeles (UCLA Health) - Los Angeles
  • UC Davis Health - Sacramento
  • Scripps Health - San Diego
  • Stanford University - Stanford

Colorado

  • University of Colorado - Aurora
  • South Denver Cardiology Associates, P.C. - Littleton

District of Columbia

  • St. Elizabeth's Medical Center - Washington D.C.
  • Medical Faculty Associates George Washington University - Washington D.C.

Georgia

  • Emory University - Atlanta
  • Georgia Arrhythmia Consultants and Research Institute - Warner Robins

Arizona

  • Banner University - Phoenix

Illinois

  • University of Illinois Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 5,350 participants
Start Date 2023-07-13
Est. Completion 2029-07-31
Phase Phase 3

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05836987

The ClinicalTrials.gov registry entry for NCT05836987 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,970-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (80% higher). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which AFSW Guided DOAC is the first listed.

NCT05836987 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT05836987 about?

NCT05836987 is a clinical study titled "The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation". REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in partic...

What is the current status of trial NCT05836987?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,350 participants. The study started on 2023-07-13. Estimated completion is 2029-07-31.

What conditions does trial NCT05836987 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT05836987?

The interventions under investigation include: AFSW Guided DOAC (DEVICE), Continuous DOAC therapy (DRUG).

Who is sponsoring clinical trial NCT05836987?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05836987 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.